Sun BioPharma, Inc. to Present Results of New Pancreatitis Study at American Pancreatic Association Meeting in Miami Beach (Globe Newswire)

UF startup Sun BioPharma, Inc., a clinical stage biopharmaceutical company specializing in disruptive therapeutics for pancreatic diseases, announced that it will present results of a new study entitled “Effect of SBP-101 in a Mouse Model of Cerulein-induced Acute Pancreatitis” at the American Pancreatic Association meeting in Miami on Nov. 1.

The study, performed in collaboration with Cedars-Sinai Medical Center in Los Angeles and funded by the National Institutes of Health, evaluated the ability of SBP-101, a polyamine metabolic inhibitor (PMI), to impact the development of acute pancreatitis using different formulations and dosing regimens.

“In some instances, administration of SBP-101 was able to decrease levels of amylase and lipase, markers of acute pancreatitis in the blood, and reduce swelling and inflammation in the pancreas,” said Michael Walker, MD, director of pancreatic research at Sun BioPharma and one of the study’s co-principal investigators.

Learn more about Sun BioPharma, Inc. to Present Results of New Pancreatitis Study at American Pancreatic Association Meeting in Miami Beach.